Drug Trial Radar · NCT05743634
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Last checked: Nov 19, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Mar 22, 2022
Primary completion
Feb 13, 2023
Study completion Feb 13, 2023
Sponsor
- Lead sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The study has been designed to test the safety,efficacy,immunogenicity of YY001,and compare to onabotulinumtoxinA (BOTOX®) and placebo, in improving the appearance of moderate to severe glabellar lines.
Conditions
- Moderate to Severe Glabellar Lines
Interventions
YY001Biological
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
OnabotulinumtoxinABiological
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
PlaceboBiological
Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase1:The incidence rate of adverse events and severe adverse events within 28 days after injectionTime frame: Within 28 days
- Phase1:The incidence rate of injection site reaction within 28 days after injectionTime frame: Within 28 days
- Phase1:The incidence rate of abnormal lab findings which have clinical significance within 28 days after injectionTime frame: Within 28 days
- Phase2:The response rate will be evaluated at 28 days by investigator at maximum frownTime frame: 28 days
- Phase2:The incidence rate of adverse events and severe adverse events within 12 weeks after injectionTime frame: within 12 weeks
- Phase2:The incidence rate of injection site reaction within 12 weeks after injectionTime frame: within 12 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The First affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Nanfang Hospital,Southern Medical University
Guangzhou, Guangdong, China
Shanghai Ninth People's Hospital,Shanghai JiaoTong University school of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital,Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.